Fuller & Thaler Asset Management
LFCR icon

Fuller & Thaler Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Fuller & Thaler Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-255,520
Closed -$2.96M – 498
2022
Q1 		$2.96M Buy
255,520
+1,325
+0.5% +$14.8K 0.02% 326
2021
Q4 		$2.82M Buy
254,195
+1,225
+0.5% +$11.9K 0.02% 327
2021
Q3 		$2.33M Sell
252,970
-1,025
-0.4% -$11.2K 0.02% 335
2021
Q2 		$2.86M Buy
253,995
+94,497
+59% +$1.09M 0.02% 310
2021
Q1 		$1.69M Sell
159,498
-14,715
-8% -$165K 0.01% 344
2020
Q4 		$1.89M Sell
174,213
-9,145
-5% -$94.5K 0.02% 332
2020
Q3 		$1.78M Sell
183,358
-10,180
-5% -$97K 0.02% 303
2020
Q2 		$1.54M Sell
193,538
-4,960
-2% -$51.2K 0.02% 308
2020
Q1 		$1.73M Buy
198,498
+17,428
+10% +$181K 0.03% 280
2019
Q4 		$2.05M Buy
181,070
+500
+0.3% +$5.32K 0.02% 290
2019
Q3 		$1.96M Buy
+180,570
New +$1.97M 0.02% 286
2018
Q3 		– Sell
-171,350
Closed -$2.55M – 605
2018
Q2 		$2.55M Hold
171,350
– – 0.03% 276
2018
Q1 		$2.24M Sell
171,350
-12,600
-7% -$166K 0.03% 269
2017
Q4 		$2.32M Sell
183,950
-58,100
-24% -$734K 0.03% 251
2017
Q3 		$3.13M Sell
242,050
-1,200
-0.5% -$15.8K 0.04% 206
2017
Q2 		$3.61M Sell
243,250
-800
-0.3% -$11.1K 0.05% 181
2017
Q1 		$2.93M Hold
244,050
– – 0.04% 185
2016
Q4 		$3.37M Buy
244,050
+212,850
+682% +$2.95M 0.05% 170
2016
Q3 		$418K Buy
+31,200
New +$378K 0.01% 282

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management's LFCR Position: Q2 2022 in Review

Fuller & Thaler Asset Management sold out of Lifecore Biomedical (LFCR) in Q2 2022, closing a stake of 255,520 shares — an estimated $2.96M sold.

Fuller & Thaler Asset Management first reported a position in LFCR in Q3 2016 and held it in 19 quarters. The position peaked at $3.61M in Q2 2017. 90 funds tracked by Wall St. Rank hold LFCR as of Q2 2022.

  • Fuller & Thaler Asset Management reported no remaining Lifecore Biomedical position as of Q2 2022 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 255,520 Lifecore Biomedical shares in Q2 2022, an estimated $2.96M.
  • Fuller & Thaler Asset Management first reported a position in Lifecore Biomedical in Q3 2016 and held it in 19 quarters.
  • Fuller & Thaler Asset Management's Lifecore Biomedical position peaked at $3.61M in Q2 2017.
  • 90 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2022.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.